Human Sarcoma Cell Lines for Biotech Companies Testing New Drugs

Patricio Ledesma

Head Of Clinical Operations at Sofpromed

5 July, 2022

Human Sarcoma Cell Lines for Biotech Companies

If you are interested in getting access to patient-derived sarcoma cell lines for drug testing, please contact us at info@sofpromed.com 

In vitro human-derived sarcoma cell lines are essential tools for conducting sarcoma pharmacogenomic studies that can help to predict the clinical response of these tumors to new drugs. 

In this article you will learn about:

What are sarcoma cell lines used for?

Sarcoma cell lines are used to study the biology of sarcoma subtypes and to test novel compounds or drug combinations designed to combat these rare, life-threatening malignancies. In addition, sarcoma cell lines are crucial to investigate the biological properties of biomarker candidates. 

How are sarcoma cell lines produced?

Patient-derived sarcoma cell lines are cultures of sarcoma patient cells that can be propagated repeatedly, growing over time, under laboratory conditions. They are generated from primary cell cultures, directly from fresh sarcoma patient tissues. 

Sarcoma: a challenging disease

Sarcomas are rare malignant tumors (about 1% of all human cancers) of mesenchymal origin with unique biological and clinical characteristics, deriving from connective tissues (soft tissue sarcomas) or bones (e. g. Ewing’s sarcoma, osteosarcoma, chondrosarcoma, chordoma). Given their great heterogeneity, complexity, and rarity, the clinical management of sarcomas is highly challenging. 

For instance, soft tissue sarcoma (STS) is a heterogeneous group of tumors comprising over 60 different histologies. The diversity in sarcoma phenotype and genotype makes treatment of this family of diseases exceptionally difficult. 

Current sarcoma treatments

Most sarcoma subtypes are still treated with traditional therapeutic modalities. Surgery with or without adjuvant or neoadjuvant radiation is the most common approach for localized disease. Over half of sarcoma patients will develop metastatic disease, which is treated with chemotherapy and, most recently, with various molecularly targeted agents. 

After 30 years, doxorubicin remains the standard of care in first line of advanced disease for many soft tissue sarcomas, while other compounds like gemcitabine, trabectedin, pazopanib, eribulin, among others, are used for second and further lines of systemic treatment. All these drugs have shown clinical activity but, unfortunately, not to the point of offering a curative attempt. Therefore, new treatments for sarcoma are desperately needed. 

The importance of robust sarcoma clinical trial design

The rare incidence of each sarcoma subtype makes clinical trials very challenging. Even sarcoma-specific trials often have enrolled patients with any sarcoma subtype, despite different etiologies and clinical manifestations, resulting in highly heterogeneous patient cohorts. 

Since the number of patients who can be recruited into clinical trials is limited for sarcomas, conducting robust preclinical studies to evaluate the eligibility of potential anticancer drugs becomes fundamental. 

What sarcoma cell lines can we offer?

Sofpromed, in collaboration with its preclinical partners, offers the following sarcoma cell line-related solutions: 

  • Patient-derived, readily available cell lines, including leiomyosarcoma, angiosarcoma, Ewing’s sarcoma, malignant peripheral nerve sheath tumor (MPNST), among other subtypes. 
  • Evaluation of molecular mechanisms related to sarcoma progression.
  • Assessment of the effect of novel drugs at the cellular and subcellular levels.
  • Pharmacogenomic studies to predict the efficacy (clinical response) of new compounds or drug combinations.

In addition to sarcoma cell lines, we can also offer patient-derived xenograft (PDX) models for specific sarcoma subtypes, which will enable additional in vivo preclinical research on new drugs. 

If you are interested in getting access to patient-derived sarcoma cell lines for drug testing, please contact us at info@sofpromed.com 

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266  pledesma@sofpromed.com 

You may also be interested…

Spanish CRO for Clinical Trials in Spain

Spanish CRO for Clinical Trials in Spain

If you are looking for a CRO to conduct a clinical trial in Spain, please contact us through this link Spain is a very strategic country for conducting clinical trials. A large number of clinical trial sponsors —not only from Spain but from all over the world,...

Sarcoma PDX Models for Drug Testing

Sarcoma PDX Models for Drug Testing

If you are interested in sarcoma patient-derived xenograft (PDX) models for drug testing, please contact us at info@sofpromed.com  In vivo sarcoma patient-derived xenograft (PDX) models are essential tools for testing the efficacy and toxicity profile of new compounds...

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266 pledesma@sofpromed.com